GLP-1 and Conception: Safety, Biomarkers, and Fertility Consid...

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Whether GLP-1 medications are appropriate during conception attempts requires careful conversation with your healthcare provider and depends on individual fertility status, metabolic health, and medication timing. Current evidence suggests GLP-1 medications are not teratogenic, but metabolic changes from weight loss may influence hormone levels and ovulation.

Planning pregnancy while managing weight involves understanding how GLP-1 therapy affects your unique metabolic profile. At PlexusDx, we believe precision-wellness decisions should integrate biomarker context, genetic predispositions in peptide pathways, and clear provider guidance—not assumptions about one-size-fits-all treatment.

How GLP-1 Medications Influence Reproductive Health During Weight Loss

GLP-1 agonists lower appetite and improve metabolic control, leading to weight loss that can restore ovulation in people with polycystic ovary syndrome (PCOS) or obesity-related infertility. However, rapid weight loss may temporarily suppress reproductive hormones, including FSH and LH, potentially affecting cycle regularity during the initial treatment phase.

The relationship between metabolic health and fertility is bidirectional. Insulin resistance, common in obesity and PCOS, impairs ovulation and increases miscarriage risk. GLP-1 therapy may improve insulin sensitivity over weeks to months, which could enhance fertility outcomes—but individual response varies significantly based on baseline metabolic status and genetic factors.

Clinical Evidence on GLP-1 Safety and Reproductive Outcomes

Animal and early human studies have not identified birth defects associated with semaglutide or tirzepatide exposure during pregnancy, but long-term pregnancy safety data in humans remains limited. Major medical organizations recommend shared decision-making between patients and providers regarding continuation or discontinuation around conception and delivery.

Evidence Domain	Key Finding
Animal teratogenicity studies	No major malformations observed at therapeutic doses in rodents and rabbits
Human pregnancy outcomes	Limited data; no confirmed birth defects reported to date, but larger registries still being compiled
Breastfeeding safety	GLP-1 peptides unlikely to cross milk barrier, but direct infant safety data is sparse
Fertility restoration in PCOS	Weight loss via GLP-1 may improve ovulation rates in approximately 60-70% of PCOS cases with obesity-driven anovulation
Miscarriage risk	Metabolic improvement may reduce miscarriage risk in insulin-resistant individuals; weight loss timing relative to conception matters

Biomarker and Genetic Context: Understanding Your Individual Response

Individual variation in GLP-1 response is partly driven by genetic variants in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic peptide receptor (GIPR), and metabolic genes like FTO and MC4R. These genetic predispositions influence how aggressively your body responds to GLP-1 therapy and may correlate with changes in reproductive hormone patterns during treatment.

Beyond genetics, biomarkers such as fasting insulin, HOMA-IR (insulin resistance index), FSH/LH ratios, and testosterone levels provide clinical context for fertility and GLP-1 response. Patients with elevated baseline insulin and androgen dysregulation may experience more significant hormonal rebalancing as weight loss progresses, potentially affecting menstrual regularity and conception timing.

Safety Framework and Provider-Guided Decision-Making

If you are actively trying to conceive, your provider may recommend pausing GLP-1 therapy 3–6 months before planned conception to assess natural cycle patterns and allow metabolic normalization. Alternatively, continuation at a stable dose may be appropriate if fertility benefits from improved metabolic health outweigh theoretical risks in your specific situation.

Open conversation with your reproductive endocrinologist or fertility specialist is essential. Share your GLP-1 therapy details, current dose, duration of treatment, and any changes in menstrual patterns. Your provider can evaluate whether biomarker-guided adjustments—such as dose tapering, temporary discontinuation, or timing strategies—best support your conception goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predispositions in peptide pathways—including GLP1R, GIPR, FTO, and MC4R variants—that influence how your body responds to GLP-1 therapy and metabolic shifts. These genetic markers should be interpreted with a qualified healthcare provider to understand their potential relevance to your fertility timeline and treatment response.

The genetic test reveals predispositions in peptide signaling and metabolic regulation, not exact medication response or fertility outcomes. For example, specific GLP1R variants may correlate with stronger appetite suppression or more pronounced weight loss, which could indirectly affect reproductive hormone patterns. However, genetics is only one part of your metabolic and reproductive picture; environmental, hormonal, and lifestyle factors are equally important.

When planning pregnancy while on GLP-1 therapy, combining genetic insights with clinical biomarkers—such as insulin levels, hormone panels, and cycle tracking—can support a more informed conversation with your fertility specialist. This precision-wellness approach helps ensure your GLP-1 therapy aligns with both metabolic health and conception goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.